Skip to main content

Production and characterization of endocrine cells derived from human pancreas organoids for the cell-based therapy of type 1 diabetes

Objective

Self-renew and multilineage potential characterize stem cells. We have recently described that pancreas progenitor cells extracted from adult donors can be expanded long-term in vitro into 3D structures, which we have termed organoids. Pancreas organoids reproduce in vitro all the features of pancreas ductal epithelia, and have a limitless expansion potential. Thus, pancreas organoids promise to boost cell therapy of type 1 diabetes. We have recently observed that progenitor cells organoids preserve their genetic stability over a long time in culture. That represents an advantage, when compared to iPS or hES derived approaches, where genetic instability raises concerns for their future therapeutic applications. While progenitor organoids are promising for the future of cell therapy, bringing stem cell-based therapies to patients requires a reliable characterization (“knowing what the cells do and how they do it”, i.e. a phenotypic and molecular biology characterization), chemically well-defined culture media, and the capacity of mass-production under GLP/GMP conditions.
The LSFM4LIFE consortium aims to the mass production of pancreas organoids for the cellular therapy of type 1 diabetes. The goals of the project are: (1) optimize growth and differentiation of human pancreas stem-cell organoids by employing phenotypic and molecular high-throughput screening (2) standardize the growth and differentiation of the organoids under well-defined biochemical conditions, and (3) achieve GLP/GMP-production of the human organoids for preclinical studies and phase I clinical studies. The close collaboration in the consortium between academic researchers and industry, as well as its cross-disciplinary composition, are essential to realize the goals of the project. The work packages of the project will have a technological impact in the form of patents and first market replication.

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /medical and health sciences/medical biotechnology/cells technologies/stem cells
  • /natural sciences/biological sciences/molecular biology
  • /medical and health sciences/clinical medicine/endocrinology/diabetes

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN
Address
Theodor W Adorno Platz 1
60323 Frankfurt Am Main
Germany
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 068 886,25

Participants (7)

THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 1 432 990
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
CELLENDES GMBH
Germany
EU contribution
€ 589 233,75
Address
Markwiesenstr 55
72770 Reutlingen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FONDAZIONE IRCCS CA' GRANDA - OSPEDALE MAGGIORE POLICLINICO
Italy
EU contribution
€ 895 000
Address
Via Francesco Sforza 28
20122 Milano
Activity type
Other
INSPHERO AG
Switzerland
EU contribution
€ 0
Address
Wagistrasse 27
8952 Schlieren
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
LONZA NETHERLANDS BV
Netherlands
EU contribution
€ 463 950
Address
Oxfordlaan 70
6229 EV Maastricht
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SPARKS & CO

Participation ended

France
EU contribution
€ 133 153,46
Address
66 Avenue Des Champs Elysees Espace 41
75008 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PROSCIENCIA BERATUNGS-GMBH
Germany
EU contribution
€ 83 186,54
Address
Auf Der Heide 11
23558 Luebeck
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)